Document is current
Any future updates will be listed below
-
Authors
Seifert, Johanna https://orcid.org/0000-0002-8678-7419
Grohmann, Renate
Toto, Sermin https://orcid.org/0000-0002-8859-6907
Reinhard, Matthias A. https://orcid.org/0000-0002-8374-5467
Bleich, Stefan
Erfurth, Andreas https://orcid.org/0000-0003-3870-3521
Schüle, Cornelius
Stübner, Susanne https://orcid.org/0000-0003-4734-1198
Glocker, Catherine https://orcid.org/0000-0003-0821-8533
-
Funding
Funding for this research was provided by:
Medizinische Hochschule Hannover (MHH)
- License Information
-
More Information
Article History
Received: 7 October 2025
Accepted: 6 December 2025
First Online: 13 December 2025
Declarations
:
: The Ethics Committee of the University of Munich and Hannover Medical School (Nr. 8100_BO_S_2018) has approved analyses using the AMSP database. This study adheres to the Declaration of Helsinki and its later amendments. Due to its observational nature, AMSP does not interfere with the ongoing treatment of the patients under surveillance.
: SB, RG, JS and ST are currently or have been project managers of the AMSP program. ST is a member of the advisory board for Otsuka Pharma GmbH and Johnson & Johnson Innovative Medicine and has received speaker´s honoraria from Johnson & Johnson Innovative Medicine, Lundbeck GmbH/Otsuka Pharma GmbH, Recordati Pharma GmbH, ROVI GmbH, and Servier. AE is a member of advisory boards for Boehringer Ingelheim, Idorsia and Recordati and has received speaker’s honoraria from Angelini, Boehringer Ingelheim, Germania, Idorsia, Janssen, Lundbeck, Mylan, Neuraxpharm, Recordati, Rovi and Sandoz. All other authors state they have no conflicts of interest to declare. The research presented in this manuscript did not receive any specific grants or funding. The AMSP drug safety project is facilitated by non-profit associations in Germany, Austria, and Switzerland. The AMSP project has been supported with unrestricted educational and research grants since 1993 by the following companies: German companies: Abbott GmbH & Co. KG, Aristo Pharma, AstraZeneca GmbH, Aventis Pharma Deutschland GmbH GE–O/R/N, Bayer Vital GmbH, Boehringer Mannheim GmbH, Bristol-Myers-Squibb, Ciba Geigy GmbH, Desitin Arzneimittel GmbH, Duphar Pharma GmbH & Co. KG, Eisai GmbH, Esparma GmbH Arzneimittel, GlaxoSmithKline Pharma GmbH & Co. KG, Hoffmann-La Roche AG Medical Affairs, Janssen-Cilag GmbH, Janssen Research Foundation, Knoll Deutschland GmbH, Lilly Deutschland GmbH Niederlassung Bad Homburg, Lundbeck GmbH & Co. KG, Novartis Pharma GmbH, Nordmark Arzneimittel GmbH, Organon GmbH, Otsuka-Pharma Frankfurt, Pfizer GmbH, Pharmacia & Upjohn GmbH, Promonta Lundbeck Arzneimittel, Recordati Pharma GmbH, Rhone-Poulenc Rohrer, ROVI GmbH, Sanofi-Synthelabo GmbH, Sanofi-Aventis Deutschland, Schering AG, SmithKlineBeecham Pharma GmbH, Solvay Arzneimittel GmbH, Synthelabo Arzneimittel GmbH, Dr. Wilmar Schwabe GmbH & Co., Thiemann Arzneimittel GmbH, Troponwerke GmbH & Co. KG, Upjohn GmbH, Wander Pharma GmbH and Wyeth-Pharma GmbH. Austrian companies: Astra Zeneca Österreich GmbH, Boehringer Ingelheim Austria, Bristol-Myers Squibb GmbH, CSC Pharmaceuticals GmbH, Eli Lilly GmbH, Germania Pharma GmbH, GlaxoSmithKline Pharma GmbH, Janssen-Cilag Pharma GmbH, Lundbeck GmbH, Novartis Pharma GmbH, Pfizer Med Inform and Wyeth Lederle Pharma GmbH. Swiss companies: AHP (Schweiz) AG, AstraZeneca AG, Bristol-Myers Squibb AG, Desitin Pharma GmbH, Eli Lilly (Suisse) S.A., Essex Chemie AG, GlaxoSmithKline AG, Janssen-Cilag AG, Lundbeck (Suisse) AG, Organon AG, Pfizer AG, Pharmacia, Sanofi-Aventis (Suisse) S.A., Sanofi-Synthelabo SA, Servier SA, SmithKlineBeecham AG, Solvay Pharma AG, Wyeth AHP (Suisse) AG and Wyeth Pharmaceuticals AG.
: Not applicable.
: Not applicable.
